Showing results (131-140 of 194) with videos related to

Sort By:
Pageof 20
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
JAMA|June 7, 2011
KIT as a therapeutic target in metastatic melanomaRichard D Carvajal, Cristina R Antonescu, Jedd D Wolchok, et al.
Future Oncology (London, England)|April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcomaMrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
JCO Precision Oncology|January 8, 2019
Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical TrialTara A Russell, Mark A Eckardt, Takashi Murakami, et al.
American Journal of Clinical Oncology|April 18, 2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue SarcomasJoseph Daniel Pennington, Fritz C Eilber, Frederick R Eilber, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.
Lancet (London, England)|June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialWilliam D Tap, Robin L Jones, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanomaAntoni Ribas, Begoña Comin-Anduix, Bartosz Chmielowski, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
Pageof 20